STI-7349 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This STI-7349 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether STI-7349 can convert its mRNA profile and IL-2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | STI-7349 (query alias: STI-7349) |
|---|---|
| Modality / target | mRNA; IL-2; IL-2 stimulants |
| Highest global status | Phase 2 |
| Originator | The Fourth Affiliated Hospital of Zhejiang University Medical College (Yiwu Hospital of Zhejiang Province, Medical Community of the Fourth Affiliated Hospital of Zhejiang University Medical College) |
| Active developers | The Fourth Affiliated Hospital of Zhejiang University Medical College (Yiwu Hospital of Zhejiang Province, Medical Community of the Fourth Affiliated Hospital of Zhejiang University Medical College), Ileukon Therapeutics, Inc. |
The MCP disease footprint includes Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, B-Cell Lymphoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07452224 | Phase 2 | Recruiting | 80 | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0. |
| NCT05978102 | Phase 1/2 | Recruiting | 183 | Number of participants of STI-7349 alone with treatment-related adverse events as assessed by CTCAE v5.0. |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A first-in-human (FIH), phase I/II open-label, dose-escalation and -expansion study of ILKN421H, an LNP mRNA encoding an IL2Rβγ selective IL-2v, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors.
Phase 1/2; n=47; evaluation: Positive. Reported fields: ORR = 77.2 %
iLeukon Therapeutics Presents Phase I Data for ILKN421H at SITC 2025
Phase 1; n=45; evaluation: Positive. Reported fields: ORR = 80.0 % ; ORR = 33.3 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
STI-7349 addresses Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, B-Cell Lymphoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—mRNA—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 12 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: IL-2 records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-12-29 | TILT Biotherapeutics Regains Rights to TILT-123 in the Greater China Area Upon Termination of License Agreement with Biotheus | Phase 1/2 | Financial terms not disclosed |
| 2023-07-27 | SQZ Biotechnologies Provides Update on Collaboration with Roche | Discovery | US$125.0M upfront; US$1,250.0M milestones |
| 2023-03-20 | Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases | Preclinical | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 3 August 2026. Counts and status fields may change as source records update.
